Belzupacap sarotalocan - Aura Biosciences/National Cancer Institute
Alternative Names: AU 011; Bel-sar; Belzupacap serotalocan; Light-activated AU-011Latest Information Update: 17 Sep 2024
At a glance
- Originator Aura Biosciences; National Cancer Institute (USA)
- Developer Aura Biosciences
- Class Antineoplastics; Drug conjugates; Immunotherapies; Phthalocyanines; Viral proteins
- Mechanism of Action Cell death stimulants; Photosensitisers; Reactive oxygen species stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Uveal melanoma
- Phase I Bladder cancer
- Preclinical Solid tumours
Most Recent Events
- 12 Sep 2024 Aura Biosciences announces intention to submit BLA for Uveal melanoma
- 12 Sep 2024 Adverse events and efficacy data from a phase-II trial in Uveal-melanoma released by Aura Biosciences ,
- 22 Apr 2024 Aura Biosciences completes a phase II trial in Uveal melanoma in USA (Intraocular) (NCT04417530)